1Peche H, Trinite B, Martinet B, et al.Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors[J]. Am J Transplant, 2005, 5(2):255-267.
2Tiao MM, Lu L, Tao R, et al. Prolongation of cardiac allograft survival by systemic administration of immature recipient dendritic cells deficient in NF-kappaB activity[J]. Ann Surg, 2005, 241(3): 497- 505.
3Holtick U, Marshall SR, Wang XN, et al. Impact of psoralen/ UVA-treatment on survival, activation, and immunostimulatory capacity of monocyte-derived dendritic cells[J]. Transplantation, 2008, 85 (6): 757-766.
4Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance[J]. Nat Rev Immunol, 2007, 7 (8): 610- 621.
5Marques MB, Tuncer HH. Photopheresis in solid organ transplant rejection[J]. J Clin Apher, 2006, 21(1): 72-77.
6Scafisbrick JJ, Taylor P, Holtick U, et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease[J]. Br J Dermatol, 2008, 158(4) : 659-678.
7Barratt-Boyes SM, Thomson AW. Dendritic cells: tools and targets for transplant tolerance[J]. Am J Transplant, 2005, 5(12) : 2807- 2813.
8Chiffoleau E, Beriou G, Dutartre P, el al. Role for thymic and splenic regulatory CD4^+ T cells induced by donor dendritic cells in al- lograft tolerance by LF15-0195 treatment[J]. J Immunol, 2002, 168 (10) : 5058-5069.
9DePaz HA, Oluwole (DO, Adeyeri AO, et al. Immature rat myeloid dendritic cells generated in low-dose granulocyte macrophage-colony stimulating factor prolong donor-specific rat cardiac allograft survival [J]. Transplantation, 2003, 75(4)I 521-528.
10Legitimo A, Consolini R, Failli A, et al. In vitro treatment of monocytes with 8-methoxypsolaren and ultraviolet A light induces dendritic cells with a tolerogenie phenotype[J]. Clin Exp Immunol, 2007, 148 (3) : 564-572.
1SociéG,Ritz J.Current issues in chronic graft-versus-host disease[J].Blood,2014,124(3):374-384.
2Filipovich AH,Weisdorf D,Pavletic S,et al.National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease:I.diagnosis and staging working group report[J].Biol Blood Marrow Transplant,2005,11(12):945-956.
3Wolff D,Gerbitz A,Ayuk F,et al.Consensus conference on clinical practice in chronic graft-versus-host disease(GVHD):first-line and topical treatment of chronic GVHD[J].Biol Blood Marrow Transplant,2010,16(12):1611-1628.
4Koc S,Leisenring W,Flowers ME,et al.Therapy for chronic graft-versus-host disease:a randomized trial comparing cyclosporine plus prednisone versus prednisone alone[J].Blood,2002,100(1):48-51.
5Lee SJ,Flowers ME.Recognizing and managing chronic graftversus-host disease[J].Hematology Am Soc Hematol Educ Program,2008:134-141.
6Sullivan KM,Witherspoon RP,Storb R,et al.Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.[J].Blood,1988,72(2):555-561.
7Sullivan KM,Siadak MF,Witherspoon RP.Cyclosporine treatment of chronic graft-versus-host disease following allogeneic bone marrow transplantation[J].Transplant Proc,1990,22(3):1336-1338.
8Jung JW,Lee YJ,Yoon SC,et al.Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease[J].Am J Ophthalmol,2015,159(3):519-527.
9Sullivan KM,Witherspoon RP,Storb R,et al.Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease:prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation[J].Blood,1988,72(2):546-554.
10Linhares YP,Pavletic S,Gale RP.Chronic GVHD:where are we?where do we want to be?will immunomodulatory drugs help?[J].Bone Marrow Transplant,2013,48(2):203-209.